Financings in Brief: Target Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Target Therapeutics: Extends stock repurchase program "by up to 500,000 additional shares." Target has already completed a buy back of 350,000 shares "authorized for repurchase upon initiation of the repurchase program in May 1996"...
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.